Using genetic probes and fluorescent scanning, the firm plans to market the $20 test for pathogens that cause urinary tract infections and biological warfare.
Fusion originally developed its synthetic capture probe technology for cancer gene fusion assays but is repurposing it to diagnose infectious diseases.
